China

Tackling tuberculosis in China through structural changes in service delivery, financial policy reform, new diagnostic tools, and delivery innovations.

A Chinese vaccine manufacturer and PATH partnered to scale a lifesaving vaccine, protecting millions of children across Asia from deadly Japanese encephalitis.

Dr. Nihal Abeysinghe and Dr. Kathleen Neuzil are pioneers of a nearly two-decade effort to prevent and control Japanese encephalitis (JE).

No longer neglected? Japanese encephalitis is a model for new vaccines to prevent other tropical diseases.

An incurable disease sometimes referred to as “brain fever” once ravaged communities across Asia. But thanks to PATH and our partners, Japanese encephalitis is no longer the threat it once was. A 15-year effort turned a little-known vaccine from China into an internationally approved immunization tool. The vaccine has now reached an estimated 300 million children—a turning point in the battle to protect people from this dreaded disease.

At PATH, we connect local innovators and decision-makers with our global network of partners to develop responsive, human-centered solutions to health challenges.